Nephrocare Health Services Limited (NSE:NEPHROPLUS)
India · Delayed Price · Currency is INR | Market Cap | 62.40B |
| Revenue (ttm) | 11.10B +32.2% |
| Net Income | 1.28B |
| EPS | 12.69 |
| Shares Out | 100.56M |
| PE Ratio | 48.90 |
| Forward PE | 38.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,056 |
| Open | 636.25 |
| Previous Close | 630.40 |
| Day's Range | 620.55 - 639.00 |
| 52-Week Range | 446.00 - 781.50 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 798.00 (+28.6%) |
| Earnings Date | Nov 3, 2026 |
About NSE:NEPHROPLUS
Nephrocare Health Services Limited provides dialysis healthcare services through a chain of kidney care clinics and dialysis centers in India, Uzbekistan, Nepal, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. The company was incorporated in 2009 and is based in Hyderabad, India. [Read more]
Financial Performance
In fiscal year 2026, NSE:NEPHROPLUS's revenue was 9.99 billion, an increase of 32.16% compared to the previous year's 7.56 billion. Earnings were 768.40 million, an increase of 14.52%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NEPHROPLUS stock is "Strong Buy." The 12-month stock price target is ₹798.00, which is an increase of 28.60% from the latest price.
News
Nephrocare Health Services Transcript: Q2 26/27
H1 revenue rose 23.6% to INR 585 crore, while adjusted EBITDA margin was 23% amid upfront investment in international expansion. The network entered Kazakhstan, and medium-term revenue growth guidance remains 15%–20%.
Nephrocare Health Services Quarterly report: Q2 2027
Nephrocare Health Services has published its Q2 2027 quarterly earnings report on November 4, 2026.
Nephrocare Health Services Slides: Q2 2027
Nephrocare Health Services has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 4, 2026.
Nephrocare Health Services Transcript: Q1 26/27
Q1 FY 2027 saw 23.7% revenue growth and 31% adjusted EBITDA growth, driven by higher treatment volumes and international expansion, with margins and ROCE improving year-on-year. The network reached 550 clinics, and international operations now contribute 45% of revenue.
Nephrocare Health Services Quarterly report: Q1 2027
Nephrocare Health Services has published its Q1 2027 quarterly earnings report on August 12, 2026.
Nephrocare Health Services Slides: Q1 2027
Nephrocare Health Services has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 12, 2026.
Nephrocare Health Services Transcript: Q4 25/26
Revenue grew 32% YoY to INR 998.8 crore, with adjusted EBITDA up 37% and PAT up 75%, driven by international expansion and operational leverage. RPT rose 13.3% to INR 2,598, and ROCE improved to 22.8%. Guidance remains at 15%-20% CAGR over 3-4 years.
Nephrocare Health Services Quarterly report: Q4 2026
Nephrocare Health Services has published its Q4 2026 quarterly earnings report on May 20, 2026.
Nephrocare Health Services Annual report: Q4 2026
Nephrocare Health Services has published its Q4 2026 annual report on May 20, 2026.
Nephrocare Health Services Transcript: Q3 25/26
Revenue grew 32% YoY in Q3 and 37% for nine months FY 2026, with international business now 41% of revenue. Adjusted EBITDA margin rose to 24.3%, and ROCE is projected to reach 24.7%. Guidance is for 15%-20% revenue CAGR over 3-4 years.
Nephrocare Health Services Quarterly report: Q3 2026
Nephrocare Health Services has published its Q3 2026 quarterly earnings report on February 11, 2026.
Nephrocare Health Services Slides: Q3 2026
Nephrocare Health Services has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 11, 2026.
Nephrocare Health Services Quarterly report: H1 2026
Nephrocare Health Services has published its H1 2026 quarterly earnings report on December 8, 2025.